These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33956087)

  • 1. The long-term use of tocilizumab in giant cell arteritis.
    Coath FL; Mukhtyar C
    Rheumatology (Oxford); 2021 Oct; 60(10):4447-4449. PubMed ID: 33956087
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?].
    Samson M; Bonnotte B
    Rev Med Interne; 2018 Feb; 39(2):75-77. PubMed ID: 29217104
    [No Abstract]   [Full Text] [Related]  

  • 3. Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study.
    Nannini C; Niccoli L; Sestini S; Laghai I; Coppola A; Cantini F
    Ann Rheum Dis; 2019 Oct; 78(10):1444-1446. PubMed ID: 31213436
    [No Abstract]   [Full Text] [Related]  

  • 4. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis.
    Gloor AD; Yerly D; Adler S; Reichenbach S; Kuchen S; Seitz M; Villiger PM
    Rheumatology (Oxford); 2018 Oct; 57(10):1795-1801. PubMed ID: 29961816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve.
    Mackie SL; Bhogal R
    Lancet Rheumatol; 2023 Dec; 5(12):e703-e705. PubMed ID: 38251559
    [No Abstract]   [Full Text] [Related]  

  • 6. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
    Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of giant cell arteritis].
    Sailler L; Pugnet G; Bienvenu B
    Rev Med Interne; 2013 Jul; 34(7):431-7. PubMed ID: 23562185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory giant cell arteritis on prednisone and tocilizumab: improvement with subsequent tuberculosis reactivation.
    Kherani I; Chin C; Kherani RB; Kherani F
    Can J Ophthalmol; 2019 Aug; 54(4):e192-e194. PubMed ID: 31358167
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab for giant cell arteritis: what is optimal?
    Kaymakci M; Warrington KJ
    Clin Exp Rheumatol; 2023 Apr; 41(4):777-779. PubMed ID: 36995336
    [No Abstract]   [Full Text] [Related]  

  • 10. Complete resolution of giant cell arteritis after tocilizumab monotherapy determined by positron emission tomography-CT.
    Akagi T; Fujita S; Mukai T; Morita Y
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30635325
    [No Abstract]   [Full Text] [Related]  

  • 11. Tocilizumab in Giant Cell Arteritis: Better Understanding the Benefits.
    Buttgereit F; Palmowski A; Esen I; Brouwer E
    Arthritis Rheumatol; 2023 Apr; 75(4):489-492. PubMed ID: 36468520
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy and tolerance of tocilizumab for corticosteroid sparing in giant cell arteritis and aortitis: Experience of Nimes University Hospital about eleven patients].
    Broner J; Arnaud E
    Rev Med Interne; 2018 Feb; 39(2):78-83. PubMed ID: 29221884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of large-vessel giant cell arteritis despite tocilizumab treatment.
    Elfishawi M; Kaymakci M; Koster MJ; Warrington KJ
    Clin Exp Rheumatol; 2023 Apr; 41(4):985-986. PubMed ID: 35930482
    [No Abstract]   [Full Text] [Related]  

  • 14. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive treatment for giant cell arteritis: where do we stand?
    Pipitone N; Salvarani C
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-5-6. PubMed ID: 26016749
    [No Abstract]   [Full Text] [Related]  

  • 16. Giant cell arteritis: An updated review of an old disease.
    Rinden T; Miller E; Nasr R
    Cleve Clin J Med; 2019 Jul; 86(7):465-472. PubMed ID: 31291180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of giant cell arteritis patients treated with tocilizumab in a single neuro-ophthalmology practice.
    Fong JW; Sharieff JA; Patel AD
    Can J Ophthalmol; 2023 Apr; 58(2):e61-e62. PubMed ID: 36126697
    [No Abstract]   [Full Text] [Related]  

  • 18. Tocilizumab for Giant Cell Arteritis-A New Giant Step in an Old Disease.
    Tamaki H; Hajj-Ali RA
    JAMA Neurol; 2018 Feb; 75(2):145-146. PubMed ID: 29255889
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Should Tocilizumab Be Used Routinely in New Patients With a Diagnosis of Giant Cell Arteritis?
    Gordon LK; Sadun AA; Van Stavern G; Lee AG
    J Neuroophthalmol; 2022 Jun; 42(2):e535-e536. PubMed ID: 35594160
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis.
    Tomelleri A; Rinaldi E; Campochiaro C; Picchio M; Dagna L
    Rheumatology (Oxford); 2023 Feb; 62(2):e24-e26. PubMed ID: 35861513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.